Sex: U
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test
Clinical narrative: Patient tested positive on 5/22 started paxlovid and completed full course. Tested negative on 5/28/22; This spontaneous case was reported by a nurse and describes the occurrence of COVID-19 (Patient tested positive on 5/22 started paxlovid and completed full course. Tested negative on 5/28/22) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Anemia and Lung nodule. Previously administered products included for Drug use for unknown indication: IODINE, SULFUR and MORPHINE. Past adverse reactions to the above products included Allergy with IODINE, MORPHINE and SULFUR. Concurrent medical conditions included Dementia, Asthma, Neuropathy, Anxiety, Hypothyroidism, Dermatitis and Hypertension. Concomitant products included DONEPEZIL HCL, MEMANTINE HCL, SALBUTAMOL (VENTOLIN [SALBUTAMOL]), SILDENAFIL CITRATE, IPRATROPIUM, AMLODIPINE, PANTOPRAZOLE, TRAZODONE, ESCITALOPRAM, LEVOTHYROXINE and LOSARTAN for an unknown indication.   On 25-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 08-Sep-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In May 2022, the patient experienced COVID-19 (Patient tested positive on 5/22 started paxlovid and completed full course. Tested negative on 5/28/22). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) (oral) from 22-May-2022 to 27-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. On 28-May-2022, COVID-19 (Patient tested positive on 5/22 started paxlovid and completed full course. Tested negative on 5/28/22) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In May 2022, SARS-CoV-2 test: positive (Positive) Patient tested positive on 5/22. On 28-May-2022, SARS-CoV-2 test: negative (Negative) Tested negative. On 31-May-2022, SARS-CoV-2 test: positive (Positive) Tested positive again.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Device Date : 31May2022  Company comment-This spontaneous case concerns a patient of unknown age and gender with no relevant medical history reported, who experienced the unexpected non serious AESI of Covid 19 on an unknown date after receiving the 3rd dose of mRNA-1273 vaccine in the covid 19 vaccination series. It was reported that the patient tested positive for covid infection in May 2022, was treated with paxlovid from 22nd May 2022 to 27th May 2022 for 6 days. Tested negative the next day after completion of Paxlovid. Three days later patient had runny nose and sneezing with positive covid test. Patient had received 1st and 2nd dose of Moderna at an interval of 31 days and approximately 195 days prior to 3rd dose.  The current pandemic situation of COVID 19 may remain as confounder. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report. Event seriousness assessed per medical judgement.; Sender's Comments: This spontaneous case concerns a patient of unknown age and gender with no relevant medical history reported, who experienced the unexpected non serious AESI of Covid 19 on an unknown date after receiving the 3rd dose of mRNA-1273 vaccine in the covid 19 vaccination series. It was reported that the patient tested positive for covid infection in May 2022, was treated with paxlovid from 22nd May 2022 to 27th May 2022 for 6 days. Tested negative the next day after completion of Paxlovid. Three days later patient had runny nose and sneezing with positive covid test. Patient had received 1st and 2nd dose of Moderna at an interval of 31 days and approximately 195 days prior to 3rd dose.  The current pandemic situation of COVID 19 may remain as confounder. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report. Event seriousness assessed per medical judgement.